Loading…
2 companies · GEL, thousands · columns ordered by revenue
| Line item | Abulpharm | Shotapharm |
|---|---|---|
| Total Revenue | 341,277 | 327,423 |
| Total COGS | -161,618 | -164,945 |
| Gross Profit | 179,659 | 162,478 |
| Gross Margin | 52.6% | 49.6% |
| Other Operating Income | 7,128 | — |
| Total Operating Expenses | -6,841 | -5,564 |
| EBITDA | 179,946 | 156,914 |
| EBITDA Margin | 52.7% | 47.9% |
| Total D&A | 0 | 0 |
| EBIT / Operating Income | 179,946 | 156,914 |
| Profit Before Tax | 179,946 | 156,914 |
| Total Income Tax | 0 | 0 |
| Net Profit / (Loss) | 179,946 | 156,914 |
| Net Margin | 52.7% | 47.9% |
| Other Comprehensive Income | 7,858 | 7,060 |
| Total Comprehensive Income | 187,804 | 163,974 |
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Abulpharm | Pharma | 52.7% | 98th pct | 110 |
| Shotapharm | Pharma | 47.9% | 95th pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.